Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

39.27USD
19 Apr 2018
Change (% chg)

$0.12 (+0.31%)
Prev Close
$39.15
Open
$39.35
Day's High
$39.85
Day's Low
$37.78
Volume
363,676
Avg. Vol
338,398
52-wk High
$45.79
52-wk Low
$11.30

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ARENA PHARMACEUTICALS INC - TO OFFER 7.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA.ARENA PHARMACEUTICALS INC - C-BRIDGE CAPITAL HAS INVESTED $50 MILLION TO FUND EVEREST MEDICINES LIMITED.ARENA PHARMACEUTICALS - AS PER AGREEMENT, CO WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.ARENA PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ARENA IS ELIGIBLE TO RECEIVE UP TO $212 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS.  Full Article

Arena Pharmaceuticals reports Q3 loss per share $0.86
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Arena Pharmaceuticals Inc ::Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results.Q3 loss per share $0.86.Q3 revenue $7.9 million.Q3 revenue view $5.5 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.Arena Pharmaceuticals Inc - ‍expect to complete full enrollment for etrasimod phase 2 study in ulcerative colitis this week​.Arena Pharmaceuticals Inc - ‍initiated etrasimod phase 2 study in primary biliary cholangitis​.  Full Article

Arena Pharmaceuticals, Eisai receive 'paragraph IV certification'
Thursday, 25 Aug 2016 

Arena Pharmaceuticals Inc : Co and Eisai Inc have received a 'paragraph IV certification' notification with respect to patents for Belviq . Notification is currently under investigation . Co and Eisai have 45 days from receipt of notification to file a patent infringement suit against ANDA filer .Patent infringement suit would result in stay of FDA approval of ANDA under statutory guidelines.  Full Article

Arena Pharmaceuticals reports Q2 loss per share $0.11
Monday, 8 Aug 2016 

Arena Pharmaceuticals Inc : Arena Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 revenue $9.5 million versus I/B/E/S view $10.4 million . Q2 loss per share $0.11 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Arena Pharma, EISAI announce FDA approval of BELVIQ XR extended-release tablets
Tuesday, 19 Jul 2016 

Arena Pharmaceuticals Inc : BELVIQ XR is expected to be available in fall of 2016. . Arena pharmaceuticals inc says in connection with approval, arena will receive a $10 million milestone payment. . EISAI Inc and Arena Pharmaceuticals announce FDA approval of Belviq XR (lorcaserin HCL) extended-release tablets .In connection with approval, arena will receive a $10 million milestone payment.  Full Article

Eisai, Arena announce regulatory approval of VENESPRI in Mexico
Thursday, 14 Jul 2016 

Arena Pharmaceuticals Inc : Eisai and Arena Pharmaceuticals announce regulatory approval of VENESPRI® (lorcaserin HCl) in Mexico . In connection with the approval, Arena will receive a $1 million milestone payment . In connection with the approval, Arena will receive a $1 million milestone payment .VENESPRI® is expected to become available later this year.  Full Article

Arena Pharmaceuticals to emphasize on its proprietary clinical stage pipeline
Thursday, 30 Jun 2016 

Arena Pharmaceuticals: Arena Pharmaceuticals Inc says strategic shifting of priorities to emphasize its proprietary clinical stage pipeline . Arena Pharmaceuticals Inc says implementation of additional cost reductions to streamline organization to support its development programs . Arena pharmaceuticals inc says will reduce its us workforce by approximately 100 employees, or 73%, primarily in areas of research, manufacturing and G&A . Estimates cost reductions to result in reduced cash expenditures for personnel by about $17 million . Plans to implement additional cost control measures to further reduce expenditures, including reductions at Swiss manufacturing facility .As a result of us workforce reduction, estimates it will incur restructuring charges, primarily in q2 of 2016, of about $6.1 million.  Full Article

Arena Pharmaceuticals files for mixed shelf of up to $250 mln
Tuesday, 14 Jun 2016 

Arena Pharmaceuticals Inc :Arena Pharmaceuticals Inc files for mixed shelf of up to $250 million - SEC filing.  Full Article

Arena Pharmaceuticals Q1 loss per share $0.09
Monday, 9 May 2016 

Arena Pharmaceuticals Inc : Amit munshi appointed chief executive officer . Arena pharmaceuticals reports first quarter 2016 financial results and provides corporate update . Q1 loss per share $0.09 . Q1 revenue $9.8 million versus i/b/e/s view $9 million .Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article